Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib vs Pirtobrutinib in cBTKi Pretreated R/R CLL/SLL
NCT07342478Phase 3Recruiting
- Sponsor
- Newave Pharmaceutical Inc.
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rocbrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Newave Pharmaceutical Inc.. Started Apr 2026; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07342478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342478.